Related Experiment Video
Updated: Sep 27, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Recurrent small cell lung cancer: update
1Department of Thoracic, Head & Neck Medical Oncology, University of Texas M.D. Anderson Cancer, Center, Houston, TX 77030-4009, USA.
Abstract:
Small cell lung cancer continues to recur and claim the lives of most of its victims. Thus, management of the patient with recurrent disease remains an active area of research. This review provides an update of clinical research experience over the past decade with relatively new conventional cytotoxins in this setting, such as the topoisomerase I inhibitors and the taxanes. Additionally, novel molecular targeted approaches with specific relevance for small cell lung cancer are discussed.
Insights
Recurrent small cell lung cancer (SCLC) management is critical. This review covers recent advances in chemotherapy, including topoisomerase I inhibitors and taxanes, plus novel molecular targeted therapies for SCLC.
Area of Science:
- Oncology
- Pulmonology
- Clinical Research
Background:
- Small cell lung cancer (SCLC) frequently recurs, leading to high mortality.
- Effective treatment strategies for recurrent SCLC remain an urgent unmet need.
Purpose of the Study:
- To review recent clinical research on managing recurrent small cell lung cancer.
- To highlight advancements in conventional cytotoxins and novel molecular targeted therapies.
Main Methods:
- Literature review of clinical research from the past decade.
- Focus on topoisomerase I inhibitors, taxanes, and molecularly targeted agents.
Main Results:
- Updated clinical experience with newer conventional cytotoxins in recurrent SCLC.
- Discussion of novel molecular targeted approaches with specific relevance to SCLC.
Conclusions:
- Advances in chemotherapy and targeted therapy offer new hope for recurrent SCLC patients.
- Continued research is essential to improve outcomes for small cell lung cancer.
